Literature DB >> 20871439

True incidence of vestibular schwannoma?

Sven-Eric Stangerup1, Mirko Tos, Jens Thomsen, Per Caye-Thomasen.   

Abstract

BACKGROUND: The incidence of diagnosed sporadic unilateral vestibular schwannomas (VS) has increased, due primarily to more widespread access to magnetic resonance imaging.
OBJECTIVE: To present updated epidemiological data on VS incidence, as well as patient age, hearing acuity, tumor size, and localization at diagnosis for the last 4 decades in an unselected population, with emphasis on developments in recent years.
METHODS: From 1976 to 2008, 2283 new cases of VS were diagnosed and registered in a national database covering 5.0 to 5.5 million inhabitants. Incidence during the period, patient sex and age, data on hearing (pure tone average and speech discrimination), and tumor size at diagnosis were retrieved from the database.
RESULTS: The incidence increased from 3.1 diagnosed VS per million per year in 1976 to a peak of 22.8 VS per million per year in 2004, which was followed by a decrease to 19.4 VS per million per year in 2008. Mean tumor size at diagnosis decreased from 30 mm in 1979 to 10 mm in 2008, whereas hearing acuity at diagnosis has improved over the years.
CONCLUSION: After a steady increase over the last 4 decades, the incidence of vestibular schwannomas appears to have peaked and decreased in recent years, stabilizing at about 19 tumors per million per year. Whereas the sex ratio and age at diagnosis have remained grossly unchanged over the years, hearing has improved, and tumor size has decreased considerably.

Entities:  

Mesh:

Year:  2010        PMID: 20871439     DOI: 10.1227/NEU.0b013e3181f22660

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  49 in total

1.  Vestibular schwannoma and pituitary adenoma in the same patient: coincidence or novel clinical association?

Authors:  Matthew L Carlson; Neil S Patel; Amy E Glasgow; Elizabeth B Habermann; Brandon R Grossardt; Michael J Link
Journal:  J Neurooncol       Date:  2016-02-22       Impact factor: 4.130

2.  Incidence of vestibular schwannomas in the United States.

Authors:  Varun R Kshettry; Jason K Hsieh; Quinn T Ostrom; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2015-05-30       Impact factor: 4.130

3.  Should we be moving to a national standardized non-gadolinium MR imaging protocol for the surveillance of vestibular schwannomas?

Authors:  Stuart Currie; David Saunders; Jeremy Macmullen-Price; Sanjay Verma; Philip Ayres; Caroline Tait; Ceryl Harwood; Andrew Scarsbrook; Ian J Craven
Journal:  Br J Radiol       Date:  2019-01-23       Impact factor: 3.039

4.  Risk Recall of Complications Associated with Vestibular Schwannoma Treatment.

Authors:  Khodayar Goshtasbi; Mehdi Abouzari; Omid Moshtaghi; Marlon Maducdoc; Brandon M Lehrich; Harrison W Lin; Hamid R Djalilian
Journal:  Otolaryngol Head Neck Surg       Date:  2019-03-19       Impact factor: 3.497

5.  The prediction of the tumor size of a vestibular schwannoma by clinical performance and vestibular function tests.

Authors:  Yujuan Zhou; Weidong Zhao; Liang Tian; Jing Yu; Yasheng Yuan; Jing Wang
Journal:  J Neurooncol       Date:  2018-09-20       Impact factor: 4.130

6.  Clinical Predictors Leading to Change of Initial Conservative Treatment of 836 Vestibular Schwannomas.

Authors:  Maarten Kleijwegt; Floris Bettink; Martijn Malessy; Hein Putter; Andel van der Mey
Journal:  J Neurol Surg B Skull Base       Date:  2019-02-04

7.  IS IMPROVED DETECTION OF VESTIBULAR SCHWANNOMA LEADING TO OVERTREATMENT OF THE DISEASE?

Authors:  John P Marinelli; Brandon R Grossardt; Christine M Lohse; Matthew L Carlson
Journal:  Otol Neurotol       Date:  2019-07       Impact factor: 2.311

8.  Antiangiogenic agents for nonmalignant brain tumors.

Authors:  Ammar H Hawasli; Joshua B Rubin; David D Tran; Douglas R Adkins; Shahid Waheed; Timothy E Hullar; David H Gutmann; John Evans; Jeffrey R Leonard; Gregory J Zipfel; Michael R Chicoine
Journal:  J Neurol Surg B Skull Base       Date:  2013-03-13

9.  Trends in acoustic neuroma management: a 20-year review of the oxford skull base clinic.

Authors:  Samuel A C Mackeith; Richard S Kerr; Chris A Milford
Journal:  J Neurol Surg B Skull Base       Date:  2013-04-01

10.  Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.

Authors:  Jaishri O Blakeley; Xiaobu Ye; Dan G Duda; Chris F Halpin; Amanda L Bergner; Alona Muzikansky; Vanessa L Merker; Elizabeth R Gerstner; Laura M Fayad; Shivani Ahlawat; Michael A Jacobs; Rakesh K Jain; Christopher Zalewski; Eva Dombi; Brigitte C Widemann; Scott R Plotkin
Journal:  J Clin Oncol       Date:  2016-03-14       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.